Physician profile
Constance Thomas
NPI 1558085399
$2,737.64
in general payments reported to CMS, 2019-2025
13 companies · $544 in 2025
The $544 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $21.47 · 2023: $968 · 2024: $1,204 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,716.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $686.17 | 2023-2025 | Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $588.90 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $556.93 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $388.26 | 2023-2025 | Ingrezza |
| Collegium Pharmaceutical, INC. | $125.00 | 2025 | Jornay Pm |
| Regeneron Healthcare Solutions, INC. | $119.69 | 2024 | Libtayo |
| Janssen Pharmaceuticals, INC | $109.04 | 2024-2025 | Invega Sustenna |
| Axsome Therapeutics, INC. | $61.55 | 2023 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $36.92 | 2025 | Cobenfy |
| Abbvie INC. | $18.02 | 2025 | |
| Lundbeck LLC | $16.67 | 2023 | Abilify Maintena |
| Indivior INC. | $16.21 | 2024 | Perseris |
| Luye Pharma (USA) LTD. | $14.28 | 2025 | Erzofri Extended-Release |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Constance Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.